Apical membrane antigen 1 (AMA1), Plasmodium falciparum 3D7 allele (AMA1)

Apical membrane antigen 1 (AMA1) is a type I transmembrane protein essential for the life cycle of the malaria parasite Plasmodium falciparum [5, 11]. It is primarily located in the micronemes of merozoites and sporozoites and is translocated to the apical surface during the invasion of host erythrocytes and hepatocytes [5, 11, 19]. AMA1's critical biological function involves forming a "moving junction" complex with the rhoptry neck protein 2 (RON2), which facilitates the parasite's entry into the host cell [1, 8, 11]. Because of its indispensable role in host cell invasion, AMA1 is a leading candidate for blood-stage malaria vaccines [5, 6, 17]. In the context of disease, AMA1 is a major target of naturally acquired immunity against malaria, and antibodies directed against it can effectively block parasite growth by disrupting the AMA1-RON2 interaction [1, 10, 17]. However, the protein exhibits significant genetic diversity, with the 3D7 allele being one of the most extensively studied variants in vaccine development [2, 9, 11]. This polymorphism presents a major therapeutic challenge, as vaccine-induced antibodies often provide strain-specific protection, failing to neutralize heterologous parasite strains [7, 10, 15, 18]. Consequently, current drug and vaccine development efforts, such as the FMP2.1/AS02A and AMA1-C1 candidates, focus on overcoming this antigenic diversity through multi-allele formulations or targeting conserved epitopes [13, 16, 18].

Other names

PfAMA1Apical membrane antigen 1Merozoite surface proteinMicroneme protein

Inhibition of the AMA1-RON2 protein-protein interaction to block host cell invasion